Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247729 | 0.85 | NR4A1 (0.48) | PTPN1LCLAT1RORCNR4A1NR4A2 | |
| Oxalic Acid SCHEMBL20968881 | 0.82 | PARP1 (0.44) | LCLAT1HSD17B10PARP1 | |
| SCHEMBL2260799 | 0.81 | LCLAT1 (0.39) | LCLAT1POLB | |
| SCHEMBL3791164 | 0.79 | MAOB (0.44) | LCLAT1RORCHSD17B10MAOA | |
| SCHEMBL28059597 | 0.79 | LCLAT1 (0.40) | PTPN1LCLAT1RORCNR4A1NR4A2 | |
| SCHEMBL23175896 | 0.79 | LCLAT1 (0.40) | LCLAT1RORCNR4A1NR4A2NR4A3 | |
| SCHEMBL3792765 | 0.79 | KDM4E (0.46) | LCLAT1HSD17B10PARP1 | |
| Hydrochloric Acid SCHEMBL29384863 | 0.78 | KDM4E (0.44) | LCLAT1HSD17B10PARP1 | |
| Water SCHEMBL27300807 | 0.78 | KDM4E (0.44) | LCLAT1HSD17B10PARP1 | |
| Hydrochloric Acid SCHEMBL28191751 | 0.78 | KDM4E (0.44) | LCLAT1HSD17B10PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | PTPN1 974/4885LCLAT1 1948/4885RORC 1826/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | PTPN1 974/4885LCLAT1 1948/4885RORC 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.